Examining the link between cotinine levels and aneurysm wall enhancement using MRI

A Prospective Cohort Study on the Correlation Between Patient Cotinine Levels and Intracranial Unruptured Aneurysm Wall Enhancement Based on High-resolution Magnetic Resonance Imaging

Observational Zhujiang Hospital · NCT06447714

This study looks at whether levels of cotinine in the body are connected to changes in the walls of unruptured brain aneurysms as seen on MRI, to help understand the risk of these aneurysms getting worse.

Quick facts

Study typeObservational
Enrollment450 (estimated)
Ages18 Years to 75 Years
SexAll
SponsorZhujiang Hospital Academic / other
Locations1 site (Guangzhou, Guangdong)
Trial IDNCT06447714 on ClinicalTrials.gov

What this trial studies

This observational study collects clinical, laboratory, and imaging data from patients with unruptured intracranial aneurysms to investigate the correlation between cotinine levels and aneurysm wall enhancement observed through high-resolution magnetic resonance imaging (HRMRI). Participants will undergo HRMRI to assess the degree of enhancement of their aneurysm walls, while also providing blood or urine samples for cotinine testing. The study aims to understand how these factors relate to the risk of aneurysm rupture and the overall prognosis of patients with intracranial aneurysms.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18-75 with diagnosed unruptured intracranial aneurysms suitable for endovascular intervention.

Not a fit: Patients with arteriovenous malformations, Moyamoya disease, or those unable to undergo high-resolution MRI will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide insights into the risk factors for aneurysm rupture, potentially leading to improved patient management and treatment strategies.

How similar studies have performed: Previous studies have indicated a relationship between aneurysm wall enhancement and rupture risk, suggesting that this approach may yield valuable insights.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age 18-75 years old, male or infertile female;
* Diagnosed as IA (intracranial aneurysm) through CTA, MRA, or DSA; And it is suitable for endovascular intervention treatment
* The patient and/or their legal representative or guardian fully understand the research purpose, voluntarily participate and sign informed consent Books;
* Patients willing to cooperate with high-resolution magnetic resonance imaging.
* Patients willing to follow up and evaluate according to clinical research protocol requirements

Exclusion Criteria:

* AVM (arteriovenous malformation), Moyamoya disease, or DAVF (dural arteriovenous fistula) related aneurysms;
* Patients with contraindications for high-resolution magnetic resonance imaging;
* Participants in clinical trials of other drugs or medical devices;
* Patients with severe underlying diseases and extremely poor clinical conditions who cannot tolerate general anesthesia surgery;
* Patients with poor compliance and inability to cooperate with follow-up;
* Possible or clear history of severe allergy to contrast agents;
* Patients with a life expectancy of less than 2 years;
* Women who are breastfeeding and preparing for pregnancy during the study period

Where this trial is running

Guangzhou, Guangdong

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Cotinine LevelsArterial Aneurysm Wall Enhancement on HRMRI
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.